Development Pipeline

EA Pharma Co., Ltd. Development Pipeline

as of August, 2024

herapeutic
Area
Development Code
(Generic name)
Development Stage Indication Note
Gastrointestinal
diseases
AJG555 Phase Ⅲ Chronic constipation in children under 2 years of age (Additional Dosage and Administration) Oral
AJM347 Phase I Inflammatory bowel disease Oral
EA1080 Phase I Inflammatory bowel disease Oral
EA3571 Phase I Nonalcoholic steatohepatitis Oral
Neurology EA4017 Phase I Chemotherapy-
induced peripheral neuropathy
Oral

※スワイプできます

※表は左右にスクロールできます

You are now leaving the EA Pharma website.

Thank you for browsing the EA Pharma website.
You are about to visit an external website.
(A new browsing window will be opened)

Click here to proceed